Discontinued App

Trial Connect

Merge eClinicalOS™ Study Connect is a companion app to Merge eClinicalOS (eCOS), a unified, cloud-based system that offers all of the EDC and clinical ...

QR Scan this code with your mobile device to download this app

Description

Merge eClinicalOS™ Study Connect is a companion app to Merge eClinicalOS (eCOS), a unified, cloud-based system that offers all of the EDC and clinical study support capabilities you need. Now, you can quickly and effortlessly review clinical trial data on a mobile device. With Study Connect, you can quickly and easily: - Set up customized alerts for specific events - Stay connected with real-time customized notifications such as adverse events, enrolled patients and site status changes - Share top-level statistics for each study with key stakeholders using the study dashboard - Expedite approval response times for critical study decisions such as patient study eligibility - Maintain security with the ability to set customized role-based permissions for individual studies - Manage randomization of subject assignments - Coordinate dispensing and inventory management To learn more, call us at 888.500.4247 or email support@eclinicalos.com Sample Uses You are heading in to a meeting with the Sponsor’s management team and you need to provide an update. Simply open the app, log in, and provide up-to-the-minute details to answer questions about patient enrollment, open queries, and site status. You are at lunch, dinner, stuck in traffic, at another site, on vacation or, really anywhere else. You may be away from your laptop, but you’re not out of range of critical notifications such as adverse events.

More

Technical specifications

Version: 2.1.0

Size: 3.7 MB

System:

Price: 0,00 €

Developed by Merge Healthcare

Day of release: 2013-07-12

Recommended age: 12+

Comments about Trial Connect

*We won´t use your data for marketing purposes, we only need to check your email

Do you know how to install the app?

Download Trial Connect free

We use cookies to improve our services and tailoring our ads to match your requirements and navigation habits. Accept · Read more